Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
$7.77
-3.4%
$7.93
$5.42
$11.41
$469.85M1.32563,133 shs720,284 shs
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$4.07
-3.1%
$4.23
$3.91
$8.45
$303.49M0.05901,574 shs354,723 shs
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$1.26
-3.8%
$2.63
$1.07
$11.76
$60.14M1.72455,812 shs214,358 shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$1.40
-12.5%
$1.78
$1.04
$11.41
$59.39M1.45432,890 shs265,359 shs
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
+1.64%-0.50%-1.23%+13.08%+7.34%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-1.41%+2.94%-1.64%-6.87%-18.60%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-2.24%+0.77%-62.46%-65.25%-19.14%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-4.76%+5.96%+10.34%-74.72%-56.52%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
4.7041 of 5 stars
4.43.00.03.83.02.50.6
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
4.5058 of 5 stars
3.23.00.04.22.71.71.9
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
3.6087 of 5 stars
3.24.00.00.02.53.31.3
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4.1951 of 5 stars
3.31.00.04.73.02.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
2.73
Moderate Buy$11.9153.27% Upside
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
2.33
Hold$6.6763.80% Upside
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
2.40
Hold$8.67587.83% Upside
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.67
Moderate Buy$11.40714.29% Upside

Current Analyst Ratings

Latest HCAT, STTK, OSUR, and VRCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/21/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
10/8/2024
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00
10/4/2024
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
10/4/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$13.00 ➝ $11.00
10/3/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$12.00
10/2/2024
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/2/2024
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$8.00 ➝ $2.00
10/2/2024
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$8.00
10/2/2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
10/1/2024
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
9/20/2024
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$16.00 ➝ $16.00
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
$299.48M1.57N/AN/A$6.38 per share1.22
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$273.54M1.11$1.33 per share3.05$5.86 per share0.69
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
$4.12M14.58N/AN/A$3.41 per share0.37
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$13.91M4.27N/AN/A$0.47 per share2.98

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
-$118.15M-$1.85N/AN/AN/A-28.87%-9.38%-4.90%11/6/2024 (Confirmed)
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
$53.65M$0.3611.31N/AN/A9.88%9.15%8.24%11/6/2024 (Confirmed)
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$87.30M-$1.85N/AN/AN/A-2,067.99%-68.65%-60.38%11/14/2024 (Estimated)
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$67M-$1.75N/AN/AN/A-625.06%-591.84%-100.16%11/14/2024 (Estimated)

Latest HCAT, STTK, OSUR, and VRCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2024N/A
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
$0.10N/A-$0.10N/AN/AN/A  
11/6/2024N/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
-$0.0350N/A+$0.0350N/AN/AN/A  
8/14/2024Q2 2024
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.43-$0.37+$0.06-$0.37$4.70 million$5.18 million
8/7/2024Q2 2024
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
$0.08$0.12+$0.04$0.17$74.96 million$75.90 million    
8/6/2024Q2 2024
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A$0.03+$0.03$0.07$53.35 million$54.34 million
8/1/2024Q2 2024
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
-$0.41-$0.42-$0.01-$0.42$0.50 million$1.61 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
N/AN/AN/AN/AN/A
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/AN/AN/AN/AN/A
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/AN/AN/AN/AN/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
N/A
1.18
1.18
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
N/A
12.17
10.84
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
N/A
7.62
7.62
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
29.58
2.36
2.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
85.00%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
93.50%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
58.74%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Insider Ownership

CompanyInsider Ownership
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
2.70%
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
3.40%
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10.50%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Health Catalyst, Inc. stock logo
HCAT
Health Catalyst
1,30060.47 million58.96 millionOptionable
OraSure Technologies, Inc. stock logo
OSUR
OraSure Technologies
63874.57 million72.03 millionOptionable
Shattuck Labs, Inc. stock logo
STTK
Shattuck Labs
10047.73 million42.72 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4042.42 million24.49 millionOptionable

HCAT, STTK, OSUR, and VRCA Headlines

Recent News About These Companies

Verrica Pharmaceuticals (NASDAQ:VRCA) Price Target Cut to $10.00
Verrica Pharmaceuticals price target lowered to $10 from $15 at TD Cowen
Verrica Pharmaceuticals announces workforce reduction
Needham downgrades Verrica Pharmaceuticals (VRCA) to a Hold

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Company Descriptions

Health Catalyst logo

Health Catalyst

NASDAQ:HCAT
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases. It offers services expertise solutions comprising data and analytics, domain expertise and education, tech-enabled managed, and implementation services; and opportunity analysis and prioritization, data governance, data modeling and analysis, quality and process improvement strategy, cost accounting, data abstraction, and population health strategies. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is headquartered in South Jordan, Utah.
OraSure Technologies logo

OraSure Technologies

NASDAQ:OSUR
OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.
Shattuck Labs logo

Shattuck Labs

NASDAQ:STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Verrica Pharmaceuticals logo

Verrica Pharmaceuticals

NASDAQ:VRCA
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.